January 11, 2012

A special focus on its diabetes franchise will define Amylin Pharmaceuticals' corporate strategy, the company's chief executive said at a recent conference sponsored by J.P. Morgan.

December 8, 2011

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

October 6, 2011

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.

September 16, 2011

A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.

September 8, 2011

Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

June 28, 2011

New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.

June 20, 2011

Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

June 20, 2011

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


June 15, 2011

A new oral medication for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim has become available in pharmacies, the companies said Wednesday.

June 9, 2011

A federal court has ruled in favor of drug maker Eli Lilly & Co. in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.

May 26, 2011

Eli Lilly is temporarily barred from using the same sales team to market two diabetes drugs, under a court order issued Thursday.

May 23, 2011

The FDA has approved a new treatment for Type 2 diabetes, the agency said. The FDA announced the approval of Tradjenta (linagliptin) made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.


May 19, 2011

A drug for cardiovascular disease made by Boehringer Ingelheim has received preferred formulary status with AARP’s Medicare Part D plans, the drug maker said Thursday.

May 16, 2011

Amylin Pharmaceuticals filed suit against Eli Lilly in federal court Monday concerning an agreement between the latter and German drug maker Boehringer Ingelheim to develop drugs for diabetes.

May 9, 2011

Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.

March 17, 2011

To help promote the third annual St. Louis Undy 5000 5K run on March 26, the Colon Cancer Alliance is introducing the “Parade of Undies” fashion show, sponsored by Boehringer Ingelheim, the maker of Dulcolax products.

March 15, 2011

Two organizations focused on chronic obstructive pulmonary disorder have joined Drive4COPD, an organization founded by drug maker Boehringer Ingelheim that seeks to raise awareness of the disease.

March 4, 2011

March is National Colorectal Cancer Awareness Month. In support of that, Boehringer Ingelheim’s Dulcolax brand this year has partnered with the Colon Cancer Alliance. Following is CCA’s CEO Andrew Spiegel on that partnership:

DSN: How has Dulcolax partnered with CCA?

February 22, 2011

In line with American Heart Month, Boehringer Ingelheim's Micardis has introduced a cardiovascular risk-reduction calculator, designed to assess patients' cardiovascular risk.

February 11, 2011

Irish biotech company Elan and German drug maker Boehringer Ingelheim will collaborate to develop and manufacture antibody-based medicines.

January 19, 2011

German drug maker Boehringer Ingelheim will purchase a manufacturing plant from U.S. biotech company Amgen, the two said.

January 11, 2011

U.S. drug maker Eli Lilly and German drug maker Boehringer Ingelheim will collaborate to develop drugs for diabetes, the companies said Tuesday.

October 13, 2010

Drug maker Boehringer Ingelheim and the Latino Commission on AIDS have launched a website targeted...

September 20, 2010

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...